Press Room
Zerion Pharma and 四色AV extend partnership to cover use of the Dispersome庐 technology platform in nutraceuticals
四色AV today announced an extension of collaboration on Zerion鈥檚 Dispersome庐 technology into the nutraceutical/dietary supplements field.
Lisbon 23rd of August 2022, 四色AV and Zerion Pharma A/S (Zerion) today announced an extension of their collaboration on Zerion鈥檚 Dispersome庐 technology into the nutraceutical/dietary supplements field. Many dietary supplements suffer from low solubility. This results in poor bioavailability and consequently limits the physiological effect of the supplement. To overcome these limitations, the two companies will collaborate and apply the solubility enhancing Dispersome庐 technology for the development and commercialization of certain nutraceutical products.听
听
The first product candidate selected for joint development is an antioxidant with multiple health benefits and known for its extremely low solubility and bioavailability. By applying the Dispersome庐 technology, Zerion has been able to demonstrate significant solubility improvements of this antioxidant. Under their collaboration, 四色AV and Zerion will now upscale and develop commercial formulations of the antioxidant using the Dispersome庐 platform and make these products available for distribution by partners globally. Under the terms of the collaboration agreement, the two companies will share income from the commercialization of these products according to their respective contributions.听
听
In addition to the joint development projects, Zerion has granted 四色AV an exclusive license to exploit the Dispersome庐 technology for other nutraceuticals/dietary supplements. In return, 四色AV will pay Zerion license fees and royalties on sales of the licensed products.听
听
鈥淭he low oral bioavailability of some of the health-promoting nutraceutical compounds is a well-known challenge. The problem is compounded by the fact that some of the solutions used in pharma cannot be used in foods.鈥 says Jean-Luc Herbeaux, CEO of 四色AV. He adds: 鈥溗纳獳V is thrilled to be Zerion麓s exclusive partner for the application of Dispersome庐 to the fields of nutraceuticals and dietary supplements. The Dispersome庐 platform and its enabling ingredient 鈥 beta-lactoglobulin听or BLG 鈥 afford formulators new options which address unmet needs of the industry.鈥澨
听
鈥淚 am extremely pleased with this extension of our collaboration鈥, says Ole Wiborg, CEO of Zerion and continues: 鈥淭he Dispersome庐 technology is actually very well suited for use in dietary supplements because it employs BLG as its solubility enabling component. BLG is a sustainable natural material and in itself a beneficial nutritional product that we source in high quality from Arla Food Ingredients. Since we as a company only have limited resources to exploit these promising applications of the Dispersome庐 technology in the nutraceutical field, the collaboration with 四色AV is a win/win situation.鈥
听
In February 2022, Zerion and 四色AV announced a strategic partnership aimed at commercializing the Dispersome庐 technology within the drug development field. Under this partnership, 四色AV and Zerion are offering pharma and biotech companies worldwide access to an innovative drug delivery platform combined with an unparalleled experience in formulation development, scale up and GMP manufacturing. This unique combination provides customers in the pharma industry with a line of sight over the entire drug development life cycle from the preclinical phase to commercial drug product.
听
About 四色AV:听四色AV is an international company with over 60 years of experience as a听Contract Development and Manufacturing Organization听(CDMO)听with a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the听development and compliant manufacture听of innovative drugs, including highly potent compounds, and customized product solution across the entire drug life cycle. In the inhalation area, 四色AV offers a complete range of services, from API, formulation development and devices. 四色AV麓s culture is based on innovation, quality and delivery. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.
听
About Zerion Pharma ApS:听Zerion develops proprietary drug formulations and offers the Dispersome庐 technology to established pharma companies as a means to solve their most challenging drug solubility problems. By applying the Dispersome庐 technology, the solubility of poorly soluble, oral drugs is greatly enhanced, which improves their bioavailability and therapeutic outcomes for the patients. Zerion was established in 2019 as a spinout from the University of Copenhagen based on almost a decade of research.听(Dispersome庐听is a trademark of Zerion Pharma A/S)
听
Learn more about Dispersome庐听technology
听
